Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

MIG Capital takes part in €35 million financing for TIBEAY and Ronopterin phase‑3b

MIG Capital is providing €2.5 million for the first time via several MIG funds and plans to increase its stake to participate in an overall €35 million financing round for TIBEAY Biosciences. The funds will finance a multicenter, regulatory‑relevant phase‑3b study for Ronopterin, manufacture of the investigational drug, supply chains and preparations for an EMA approval application in Europe. Ronopterin is a first‑in‑class agent that selectively inhibits iNOS to reduce secondary brain injury after severe traumatic brain injury. The round is led by Athos; other investors include Meneldor and Oost NL. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2009, MIG Holdings Aktie has already paid €6.00 in dividends. The last payout was in July 2009.

Fundamentals

Metric	Value
Market capitalization	€4.05bn
Number of shares	107.09m
52-week high/low	€40.24 - €31.52
Dividend yield	20.30%
Dividends TTM	€0.59
Beta	0.80
P/E ratio	-
PEG ratio	-
P/B ratio	-
P/S ratio	-

Company profile

Marfin Investment Group Holdings S.A., an investment holding company, focuses on investment in equities in Greece and South-Eastern Europe. The company engages in the real estate management; ship management; overseas and coastal transportation; production and distribution of dairy products, animal feed, vegetables, and frozen foods; restaurants and café-patisseries; and beverage and fast-food businesses. It also provides education services; integrated software solutions; IT systems and software applications; aircraft maintenance and repair; advertising services; and computer and software solutions, as well as its related application services. The company is based in Athens, Greece.